| Literature DB >> 26420628 |
Jui-Feng Hsu1, Hsu-Liang Chang2, Ming-Ju Tsai3, Ying-Ming Tsai4, Yen-Lung Lee5, Pei-Huan Chen6, Wen-Chieh Fan7, Yu-Chung Su8, Chih-Jen Yang9,10,11.
Abstract
BACKGROUND: Implantable venous access port (IVAP)-related blood stream infections (BSIs) are one of the most common complications of implantable venous ports. The risk factors and pathogens for IVAP-related BSIs are still controversial.Entities:
Mesh:
Year: 2015 PMID: 26420628 PMCID: PMC4588233 DOI: 10.1186/s12957-015-0707-2
Source DB: PubMed Journal: World J Surg Oncol ISSN: 1477-7819 Impact factor: 2.754
Clinical characteristics of the patients using different ports
| Variables | All patients | Bard | TYCO |
|
|---|---|---|---|---|
|
| 552 | 113 (20 %) | 439 (80 %) | |
| Sex— | 0.0003 | |||
| Female | 317 (57 %) | 48 (42 %) | 269 (61 %) | |
| Male | 235 (43 %) | 65 (58 %) | 170 (39 %) | |
| Age—mean ± SD | 59.9 ± 12.3 | 63.6 ± 11 | 58.9 ± 12.4 | 0.0002 |
| Age— | 0.0050 | |||
| Age ≤ 65 | 369 (67 %) | 63 (56 %) | 306 (70 %) | |
| Age > 65 | 183 (33 %) | 50 (44 %) | 133 (30 %) | |
| Malignancy (indication for the port)— | <0.0001 | |||
| Lung cancer | 105 (19 %) | 34 (30 %) | 71 (16 %) | |
| Head and neck tumor | 29 (5 %) | 4 (4 %) | 25 (6 %) | |
| Breast cancer | 132 (24 %) | 8 (7 %) | 124 (28 %) | |
| Esophageal cancer | 5 (1 %) | 0 (0 %) | 5 (1 %) | |
| Gastric cancer | 22 (4 %) | 7 (6 %) | 15 (3 %) | |
| Colorectal cancer | 114 (21 %) | 28 (25 %) | 86 (20 %) | |
| Urological cancer | 55 (10 %) | 14 (12 %) | 41 (9 %) | |
| Ovary cancer and cervical cancer | 47 (9 %) | 9 (8 %) | 38 (9 %) | |
| Hepatobiliary and pancreatic tumor | 9 (2 %) | 4 (4 %) | 5 (1 %) | |
| Leukemia and lymphoma | 25 (5 %) | 3 (3 %) | 22 (5 %) | |
| Other malignancies | 9 (2 %) | 2 (2 %) | 7 (2 %) | |
| Malignancy (lung cancer or others)— | 0.0008 | |||
| Lung cancer | 105 (19 %) | 34 (30 %) | 71 (16 %) | |
| Other malignancies | 447 (81 %) | 79 (70 %) | 368 (84 %) | |
| Surgeon— | 0.0031 | |||
| Surgeon A | 142 (26 %) | 37 (33 %) | 105 (24 %) | |
| Surgeon B | 358 (65 %) | 74 (65 %) | 284 (65 %) | |
| Other surgeons | 52 (9 %) | 2 (2 %) | 50 (11 %) | |
| Port infection (+)— | 34 (6 %) | 2 (2 %) | 32 (7 %) | 0.0295 |
| Gram-positive bacteria | 15 (44 %) | 2 (100 %) | 13 (41 %) | 0.1009 |
|
| 13 (38 %) | 2 (100 %) | 11 (34 %) | 0.0639 |
| Gram-negative bacteria | 19 (56 %) | 1 (50 %) | 18 (56 %) | 0.8629 |
|
| 10 (29 %) | 0 (0 %) | 10 (31 %) | 0.3467 |
|
| 4 (12 %) | 0 (0 %) | 4 (13 %) | 0.5945 |
Fig. 1The TYCO venous port had a higher infection rate than the Bard type (p = 0.0185)
Clinical characteristics of the patients with or without port infections
| Variables | All patients | Port infection (−) | Port infection (+) |
|
|---|---|---|---|---|
|
| 552 | 518 (94 %) | 34 (6 %) | |
| Gender— | 0.0071 | |||
| Female | 317 (57 %) | 305 (59 %) | 12 (35 %) | |
| Male | 235 (43 %) | 213 (41 %) | 22 (65 %) | |
| Age—mean ± SD | 59.9 ± 12.3 | 59.5 ± 12.3 | 64.9 ± 11.1 | 0.0132 |
| Age— | 0.0312 | |||
| Age ≤ 65 years | 369 (67 %) | 352 (68 %) | 17 (50 %) | |
| Age > 65 years | 183 (33 %) | 166 (32 %) | 17 (50 %) | |
| Malignancy (indication for the port)— | 0.0005 | |||
| Lung cancer | 105 (19 %) | 88 (17 %) | 17 (50 %) | |
| Head and neck tumor | 29 (5 %) | 27 (5 %) | 2 (6 %) | |
| Breast cancer | 132 (24 %) | 130 (25 %) | 2 (6 %) | |
| Esophageal cancer | 5 (1 %) | 5 (1 %) | 0 (0 %) | |
| Gastric cancer | 22 (4 %) | 22 (4 %) | 0 (0 %) | |
| Colorectal cancer | 114 (21 %) | 111 (21 %) | 3 (9 %) | |
| Urological cancer | 55 (10 %) | 50 (10 %) | 5 (15 %) | |
| Ovary cancer and cervical cancer | 47 (9 %) | 43 (8 %) | 4 (12 %) | |
| Hepatobiliary and pancreatic tumor | 9 (2 %) | 9 (2 %) | 0 (0 %) | |
| Leukemia and lymphoma | 25 (5 %) | 25 (5 %) | 0 (0 %) | |
| Other malignancies | 9 (2 %) | 8 (2 %) | 1 (3 %) | |
| Malignancy (lung cancer or others)— | <0.0001 | |||
| Lung cancer | 447 (81 %) | 430 (83 %) | 17 (50 %) | |
| Other malignancies | 105 (19 %) | 88 (17 %) | 17 (50 %) | |
| Surgeon— | 0.5273 | |||
| Surgeon A | 142 (26 %) | 131 (25 %) | 11 (32 %) | |
| Surgeon B | 358 (65 %) | 339 (65 %) | 19 (56 %) | |
| Other surgeons | 52 (9 %) | 48 (9 %) | 4 (12 %) |
Catheter-related bacteremia-related pathogens in this study
| Bacteria | Number |
|---|---|
| Gram-positive bacteria | 15 |
|
| 13 |
| Oxacillin-susceptible (OSSA) | 8 |
| Oxacillin-resistant (ORSA) | 5 |
|
| 1 |
|
| 1 |
| Gram-negative bacteria | 19 |
|
| 10 |
|
| 2 |
|
| 2 |
|
| 1 |
|
| 2 |
|
| 1 |
|
| 1 |
|
| 4 |
Cox proportional hazard regression analysis to identify the factors associated with port-infection-free survival
| Clinical features | Univariate analysis | Multivariate analysis—maximal model | Multivariate analysis—reduced model | |||
|---|---|---|---|---|---|---|
| HR (95 % CI) |
| HR (95 % CI) |
| HR (95 % CI) |
| |
| Port type (TYCO vs. Bard) | 4.759 (1.137–19.927) | 0.0327 | 7.643 (1.795–32.535) | 0.0059 | 7.105 (1.688–29.904) | 0.0075 |
| Gender (male vs. female) | 2.849 (1.408–5.766) | 0.0036 | 1.974 (0.934–4.172) | 0.0748 | ||
| Age (>65 vs. ≤65 years) | 2.262 (1.154–4.436) | 0.0175 | 2.083 (1.043–4.157) | 0.0375 | 2.320 (1.179–4.564) | 0.0148 |
| Malignancy (lung cancer vs. others) | 5.121 (2.610–10.050) | <0.0001 | 4.885 (2.362–10.104) | <0.0001 | 5.807 (2.946–11.447) | <0.0001 |
| Surgeon (surgeon A vs. others) | 0.862 (0.273–2.718) | 0.8000 | 0.872 (0.271–2.810) | 0.8184 | ||
| Surgeon (surgeon B vs. others) | 0.508 (0.171–1.511) | 0.2234 | 0.86 (0.285–2.594) | 0.7887 | ||
Clinical characteristics of the patients with or without local infections
| Variables | All patients | Local infection (−) | Local infection (+) |
|
|---|---|---|---|---|
|
| 34 | 23 (68 %) | 11 (32 %) | |
| Gender— | 0.4590 | |||
| Female | 12 (35 %) | 7 (30 %) | 5 (45 %) | |
| Male | 22 (65 %) | 16 (70 %) | 6 (55 %) | |
| Age—mean ± SD | 64.9 ± 11.1 | 66.9 ± 10.1 | 60.8 ± 12.3 | 0.1339 |
| Age— | 0.2714 | |||
| Age ≤ 65 years | 17 (50 %) | 10 (43 %) | 7 (64 %) | |
| Age > 65 years | 17 (50 %) | 13 (57 %) | 4 (36 %) | |
| Malignancy (indication for the port)— | 0.8519 | |||
| Lung cancer | 17 (50 %) | 11 (48 %) | 6 (55 %) | |
| Head and neck tumor | 2 (6 %) | 2 (9 %) | 0 (0 %) | |
| Breast cancer | 2 (6 %) | 1 (4 %) | 1 (9 %) | |
| Colorectal cancer | 3 (9 %) | 2 (9 %) | 1 (9 %) | |
| Urological cancer | 5 (15 %) | 4 (17 %) | 1 (9 %) | |
| Ovary cancer and cervical cancer | 4 (12 %) | 3 (13 %) | 1 (9 %) | |
| Other malignancies | 1 (3 %) | 0 (0 %) | 1 (9 %) | |
| Malignancy (lung cancer or others)— | 0.7139 | |||
| Lung cancer | 17 (50 %) | 11 (48 %) | 6 (55 %) | |
| Other malignancies | 17 (50 %) | 12 (52 %) | 5 (45 %) | |
| Surgeon— | 0.6647 | |||
| Surgeon A | 11 (32 %) | 7 (30 %) | 4 (36 %) | |
| Surgeon B | 19 (56 %) | 14 (61 %) | 5 (45 %) | |
| Other surgeons | 4 (12 %) | 2 (9 %) | 2 (18 %) | |
| Pathogen— | ||||
| Gram-positive Bacteria | 15 (44 %) | 8 (35 %) | 7 (64 %) | 0.1512 |
|
| 13 (38 %) | 6 (26 %) | 7 (64 %) | 0.0597 |
| Gram-negative Bacteria | 19 (56 %) | 16 (70 %) | 3 (27 %) | 0.0301 |
|
| 10 (29 %) | 8 (35 %) | 2 (18 %) | 0.4375 |
|
| 4 (12 %) | 3 (13 %) | 1 (9 %) | 0.7379 |